Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 62 citing articles:

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
Hang‐Long Li, Gregory Y.H. Lip, Qi Feng, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 137
Comparison of Effectiveness Among Different Sodium‐Glucose Cotransoporter‐2 Inhibitors According to Underlying Conditions: A Network Meta‐Analysis of Randomized Controlled Trials
Ryoma Kani, Atsuyuki Watanabe, Yoshihisa Miyamoto, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 16
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Kristian B. Filion, Lisa M. Lix, Oriana HY Yu, et al.
BMJ (2020), pp. m3342-m3342
Open Access | Times Cited: 90
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 82
The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
Hung-Yi Chen, Jing‐Yang Huang, Wun-Zhih Siao, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 81
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
Adam J. Nelson, Neha J. Pagidipati, Vanita R. Aroda, et al.
Circulation (2021) Vol. 144, Iss. 1, pp. 74-84
Open Access | Times Cited: 56
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan
Yu‐Chen Su, Jia‐Horung Hung, Kai‐Cheng Chang, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2232584-e2232584
Open Access | Times Cited: 35
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
Shih‐Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 47
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Dapeng Zhang, Li Xu, Lefeng Wang, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 45
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
David Thein, M. Christiansen, Ulrik M. Mogensen, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 40
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Thahesh Tharmaraja, Jamie Sin Ying Ho, Ching‐Hui Sia, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13, pp. 204062232210869-204062232210869
Open Access | Times Cited: 24
Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
Thomas M. Caparrotta, Andrew M. Greenhalgh, Karen Osinski, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 4, pp. 991-1028
Open Access | Times Cited: 32
Risk of diabetic macular oedema with sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes patients: A multi‐institutional cohort study in Taiwan
Yu‐Chen Su, Shih‐Chieh Shao, Edward Chia‐Cheng Lai, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 9, pp. 2067-2076
Closed Access | Times Cited: 32
Benefits of SGLT2 inhibitors in arrhythmias
Jinghan Gao, Genlong Xue, Ge Zhan, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 21
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
Jae-Hyun Lim, You-Jung Choi, Bong Sung Kim, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
Hsin‐Fu Lee, Shao‐Wei Chen, Jia‐Rou Liu, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 29
Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
Marco Castellana, Filippo Procino, Rodolfo Sardone, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 28
Comparative Cardiovascular Outcomes of Dapagliflozin Versus Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
Rhuna Dhana, Yousef H Aqel, Anurag Rawat, et al.
Cureus (2025)
Open Access
Effectiveness of Minimally Invasive Hepatectomy in Patients with Early or Intermediate-Stage Hepatocellular Carcinoma: A Multi-Institutional Cohort Study in an Asian Population
Hung-Kai Chen, Kai‐Cheng Chang, Shih‐Chieh Shao, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 879-890
Open Access
Application of Healthcare ‘Big Data’ in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN)
Jenni Ilomäki, J. Simon Bell, Adrienne Chan, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 897-913
Open Access | Times Cited: 24
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
Shih‐Chieh Shao, Kai‐Cheng Chang, Swu‐Jane Lin, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 23
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
Jayoung Lim, In‐Chang Hwang, Hong‐Mi Choi, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0269414-e0269414
Open Access | Times Cited: 15
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Tricia Santos Cavaiola, Jeremy Pettus
Diabetes Metabolic Syndrome and Obesity (2018) Vol. Volume 11, pp. 133-148
Open Access | Times Cited: 25
Investigating the Effects of Dapagliflozin on Cardiac Function, Inflammatory Response, and Cardiovascular Outcome in Patients with STEMI Complicated with T2DM after PCI
Liming Xue, Xian Yuan, Shuguang Zhang, et al.
Evidence-based Complementary and Alternative Medicine (2021) Vol. 2021, pp. 1-6
Open Access | Times Cited: 18
Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in Taiwan
Kai‐Cheng Chang, Shih‐Chieh Shao, Hui‐Yu Chen, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1157-1157
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top